AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11854636
Drug: Normal oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal oral glucose tolerance test results
Trial: 10188899
Drug: Pre-operative chemotherapy
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative chemotherapy (mitomycin-C 8 mg m(‐2), vinblastine 6 mg m(‐2), cisplatin 50 mg m(‐2) - MVP) followed by surgery
Trial: 7564895
Drug: Hexyl nicotinate
RxNorm normalized name: Hexyl nicotinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexyl nicotinate (HN) 0.5% ethanol solution
Trial: 7564895
Drug: Methyl nicotinate
RxNorm normalized name: Methyl Nicotinate
DrugBank: Methyl nicotinate (DB13882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl nicotinate (MN) 5% ethanol solution
Trial: 2250114
Drug: Combined heat
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined heat and radiation therapy (thermoradiotherapy)
Trial: 6985998
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of aspirin per day
Trial: 8771219
Drug: Combined cognitive-behavioral/psychopharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cognitive-behavioral/psychopharmacological treatment (nortriptyline or fluoxetine in AN-R, fluoxetine or amineptine in AN-BP)
Trial: 8771219
Drug: Fluoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine treatment in AN-R patients
Trial: 8771219
Drug: Fluoxetine or
RxNorm normalized name: fluoxetine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine or amineptine treatment in AN-BP patients
Trial: 2251437
Drug: Salbutamol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (100 mcg, 2 puffs)
Trial: 2251437
Drug: Oxitropium bromide
RxNorm normalized name: oxitropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitropium bromide (100 mcg, 2 puffs)
Trial: 2251437
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Salbutamol and Oxitropium bromide
Trial: 6109480
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A - BCAA solution with 12 g N (852 mmol) and 41.1% BCAA
Trial: 6109480
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B - Control solution with 18 g N (1278 mmol) and 21.1% BCAA
Trial: 28114265
Drug: NSAIDs (ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (ketorolac tromethamine 10 mg, 2 tablets daily for 2 days and amoxicillin 500 mg, 3 tablets daily for 7 days) + corticosteroids (betamethasone 2 mL injection within 10 hours after surgery)
Trial: 28114265
Drug: NSAIDs (ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (ketorolac tromethamine 10 mg, 2 tablets daily for 2 days and amoxicillin 500 mg, 3 tablets daily for 7 days)
Trial: 25894843
Drug: Homotaurine 100
RxNorm normalized name: HYPOTAURINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homotaurine 100 mg
Trial: 19473833
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus pemetrexed (500 mg/m2 pemetrexed IV followed by 75 mg/m2 cisplatin IV on day 1)
Trial: 19473833
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus gemcitabine (1250 mg/m2 on days 1 and 8 and 75 mg/m2 cisplatin on day 1)
Trial: 11800185
Drug: Daily brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily brief preference assessments
Trial: 7979291
Drug: Dapsone 200
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone 200 mg weekly
Trial: 7979291
Drug: Dapsone 200
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone 200 mg plus pyrimethamine 25 mg weekly
Trial: 7979291
Drug: Dapsone 200
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone 200 mg plus pyrimethamine 75 mg weekly
Trial: 29194698
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg oral dose with verapamil
Trial: 22836861
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral refeeding (RORF)
Trial: 18551287
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of T1-weighted images (T1WI), T2-weighted images (T2WI), and fluid-attenuated inversion recovery (FLAIR) images
Trial: 18551287
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of T1WI and FLAIR images
Trial: 18551287
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of T2WI and FLAIR images
Trial: 18551287
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of T1WI and T2WI images
Trial: 18551287
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of T1WI, T2WI, and FLAIR images
Trial: 14745057
Drug: Lidocaine 5
RxNorm normalized name: lidocaine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 5 mg/kg IV during 30 minutes
Trial: 14745057
Drug: Mexiletine titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine titrated from 400 to 1,000 mg per day (mean 737 mg/day)
Trial: 9852694
Drug: pentazocine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pentazocine 0.3 mg.kg‐1 followed by thiamylal 5 mg.kg‐1
Trial: 9852694
Drug: pentazocine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pentazocine 0.6 mg.kg‐1 followed by thiamylal 5 mg.kg‐1
Trial: 9852694
Drug: thiamylal 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thiamylal 5 mg.kg‐1
Trial: 8208390
Drug: Phentolamine (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (35 mg)
Trial: 2927132
Drug: Ethanol (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.7 g/kg, p.o.)
Trial: 27501650
Drug: 30-mL normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-mL normal saline bolus
Trial: 22554751
Drug: Etching with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etching with 30% phosphoric acid for 15 seconds with daily brushing
Trial: 22554751
Drug: Etching with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etching with 30% phosphoric acid for 30 seconds with daily brushing
Trial: 22554751
Drug: Non-etched control
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-etched control with daily brushing
Trial: 18852529
Drug: 5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/d glycine
Trial: 18852529
Drug: 5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/d placebo
Trial: 11262783
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (300 U/kg twice a week)
Trial: 11262783
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (300 U/kg twice a week) and preoperative autologous blood donation
Trial: 11262783
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood administration without concurrent erythropoietin
Trial: 3377382
Drug: Pilocarpine 4%
RxNorm normalized name: PILOCARPINE 4% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine 4% gel
Trial: 28432266
Drug: Intra-Arterial Treatment
RxNorm normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-Arterial Treatment (IAT)
Trial: 25369890
Drug: Calcifediol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcifediol (20 μg per day)
Trial: 25369890
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (20 μg or 800 IU per day)
Trial: 23289005
Drug: Percutaneous adhesiolysis
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous adhesiolysis with caudal epidural injections, including 5 mL of 2% preservative-free lidocaine, 6 mL of 10% hypertonic sodium chloride solution, and 6 mg of non-particulate betamethasone.
Trial: 11344343
Drug: Salmeterol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol plus low-dose fluticasone (42 microg of salmeterol and 88 microg of FP)
Trial: 11344343
Drug: Higher-dose fluticasone
RxNorm normalized name: fluticasone Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose fluticasone (220 microg)
Trial: 11344343
Drug: Salmeterol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol plus low-dose FP
Trial: 7937520
Drug: R(−)ibuprofen (intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R(−)ibuprofen (intravenously infused as a racemic mixture)
Trial: 7937520
Drug: R(−)ibuprofen (intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R(−)ibuprofen (intravenously infused alone)
Trial: 7937520
Drug: S(+)ibuprofen (dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)ibuprofen (dosed as S(+)ibuprofen)
Trial: 7937520
Drug: R(−)ibuprofen (concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R(−)ibuprofen (concurrent administration with S(+)ibuprofen)
Trial: 7937520
Drug: R(−)ibuprofen (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R(−)ibuprofen (intravenous dose)
Trial: 7937520
Drug: R(−)ibuprofen lysinate
RxNorm normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: R(−)ibuprofen lysinate (oral dose)
Trial: 7937520
Drug: S(+)ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: S(+)ibuprofen
Trial: 7937520
Drug: R(−)ibuprofen (dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R(−)ibuprofen (dosed alone)
Trial: 8971313
Drug: Indomethacin 200
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin 200 mg
Trial: 1485176
Drug: ondansetron 32
RxNorm normalized name: ondansetron 32 MG in 50 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 32 mg IV x 1
Trial: 1485176
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg IV x 1
Trial: 1485176
Drug: ondansetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 0.15 mg/kg IV every 4 hours x 3
Trial: 16335904
Drug: Citalopram (8-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (8-week administration)
Trial: 19143690
Drug: Tramadol 2
RxNorm normalized name: traMADol 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 2 mg.kg(‐1)
Trial: 9579457
Drug: Intravenous albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous albuterol
Trial: 30965138
Drug: High-dose methotrexate/cytarabine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate/cytarabine-based induction followed by ASCT
Trial: 23587090
Drug: Text message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message reminder system for oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they do not respond to indicate test completion.
Trial: 12878366
Drug: Indapamide SR
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide SR 1.5 mg once daily for 3 months
Trial: 10868557
Drug: Combination hydrocodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination hydrocodone 7.5 mg and ibuprofen 200 mg
Trial: 10868557
Drug: Combination oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination oxycodone 5 mg and acetaminophen 325 mg
Trial: 9200361
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of erythromycin estolate (40 mg/kg/d; maximum dose 1 g/d)
Trial: 9200361
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of erythromycin estolate (40 mg/kg/d; maximum dose 1 g/d)
Trial: 1443486
Drug: Subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration with 1% lignocaine
Trial: 3026006
Drug: Sulbactam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbactam (0.5 g) plus ampicillin (1 g)
Trial: 31329985
Drug: Physical therapy-related
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy-related tweets
Trial: 26488833
Drug: Text messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text messaging intervention (daily texts for adherence and weekly for symptoms for 21-28 days)
Trial: 18305998
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment with T4
Trial: 12628877
Drug: Oral azithromycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral azithromycin, 500 mg on day 1 and 250 mg per day for days 2 to 5
Trial: 12628877
Drug: Oral levofloxacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin, 500 mg q24h for 7 days
Trial: 11387366
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy and autologous stem-cell transplantation (ASCT)
Trial: 11387366
Drug: Conventional consolidation/maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional consolidation/maintenance chemotherapy (CC)
Trial: 3312701
Drug: Oral TA-064
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TA-064 (20 mg)
Trial: 3312701
Drug: Intravenous dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dobutamine (5 micrograms/kg/min)
Trial: 26906023
Drug: Daily use
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use of an antiretroviral tablet (tenofovir or Truvada)
Trial: 26906023
Drug: Daily use
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use of tenofovir gel
Trial: 21255959
Drug: Substance abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance abuse treatment (n = 113)
Trial: 21255959
Drug: No substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No substance abuse treatment (n = 127)
Trial: 10681321
Drug: DZ-2640 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZ-2640 25 mg
Trial: 10681321
Drug: DZ-2640 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZ-2640 400 mg
Trial: 10681321
Drug: DZ-2640 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZ-2640 100 mg (fasted state)
Trial: 10681321
Drug: DZ-2640 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZ-2640 100 mg (fed state)
Trial: 10681321
Drug: DZ-2640 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZ-2640 (all doses)
Trial: 9316463
Drug: Orlistat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (200 mg) with a pure fat meal (10% Intralipid)
Trial: 9316463
Drug: Orlistat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (200 mg) with a meal containing free fatty acids
Trial: 9316463
Drug: Orlistat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (200 mg) with an albumin-glucose meal
Trial: 8420767
Drug: Fibrin adhesive
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin adhesive (0.8‐1.4 ml) injected after fine needle puncture
Trial: 20435858
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (HS) inhalation for 4 weeks, twice daily
Trial: 20435858
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (IS) inhalation for 4 weeks, twice daily
Trial: 18388031
Drug: cilostazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilostazol (200 mg/d)
Trial: 18388031
Drug: pentoxifylline (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pentoxifylline (1200 mg/d)
Trial: 12108312
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose regimen of quinine (20 mg salt/kg initial loading dose, followed by 10 mg salt/kg maintenance dose)
Trial: 12108312
Drug: Regimen without
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen without loading dose (15 mg salt/kg)
Trial: 12108312
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose regimen of quinine
Trial: 12108312
Drug: Regimen without
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen without loading dose
Trial: 7814759
Drug: Two permucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two permucosal cylindric implants
Trial: 11573634
Drug: bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 2.5 mg plus fentanyl 25 microg (group F)
Trial: 11573634
Drug: bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 2.5 mg plus diamorphine 250 microg (group D)
Trial: 28664420
Drug: Positive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive treatment beliefs
Trial: 28664420
Drug: Negative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative treatment beliefs
Trial: 24641883
Drug: 1.6 g/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 g/kg/d protein (2×‐RDA)
Trial: 24641883
Drug: 2.4 g/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g/kg/d protein (3×‐RDA)
Trial: 24641883
Drug: 0.8 g/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg/d protein (RDA)
Trial: 22254072
Drug: Total calcium
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total calcium intake with supplements
Trial: 15986266
Drug: Comprehensive intravenous
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive intravenous and oral hydration
Trial: 12560310
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (70 mg x kg(‐1) at induction followed by 30 mg x kg(‐1) x hr(‐1))
Trial: 10329891
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy (betamethasone 12 mg IM, repeated after 24 hours)
Trial: 2007038
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: Injection of 8 ml mixture of 2% lidocaine hydrochloride jelly and saline at a dilution of 1:3
Trial: 2007038
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: Injection of 8 ml mixture of 2% lidocaine hydrochloride jelly and saline at a dilution of 1:1
Trial: 31064808
Drug: Meningococcal B
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal B (4CMenB) vaccine
Trial: 30371895
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate 1000-mg + prednisone 5-mg + ADT (AAP group)
Trial: 26245497
Drug: 3-day dexamethasone
RxNorm normalized name: dexamethasone 3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day dexamethasone (8 mg IV on day 1, followed by oral dexamethasone on days 2 and 3)
Trial: 26245497
Drug: Single-dose dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose dexamethasone (8 mg IV on day 1)
Trial: 22659656
Drug: Probucol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (500 mg/d) plus levamlodipine besylate (2.5 mg/d) plus benazepril (10 mg/d)
Trial: 22659656
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (levamlodipine besylate 2.5 mg/d plus benazepril 10 mg/d)